Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
| Status: | Completed |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 50 - 90 |
| Updated: | 2/24/2019 |
| Start Date: | September 2015 |
| End Date: | December 1, 2018 |
In this study, the investigators aim to determine whether injecting botulinum toxin into
epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation
(POAF) after cardiac surgery. The investigators will test the hypothesis that botulinum toxin
injected into the epicardial fat pads reduces POAF and length of stay (LOS) without
increasing adverse events. This will be a prospective randomized trial of 130 patients
undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery with
cardiopulmonary bypass. Patients will be randomized to receive either botulinum toxin (50
units per fat pad, n=65) or normal saline/placebo (1 mL per fat pad, n=65) injected into
epicardial fat pads. All patients will receive standardized anesthetic, surgical, and
post-surgical care. The primary outcome in this study will be time to occurrence of
in-hospital POAF. Based on previous work and a pilot trial showing a pronounced reduction
(relative risk reduction 77%) in POAF after injecting botulinum into the epicardial fat pads,
the investigators anticipate a significant reduction in the risk for POAF with epicardial
botulinum in this cohort, which includes valve surgery patients.
epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation
(POAF) after cardiac surgery. The investigators will test the hypothesis that botulinum toxin
injected into the epicardial fat pads reduces POAF and length of stay (LOS) without
increasing adverse events. This will be a prospective randomized trial of 130 patients
undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery with
cardiopulmonary bypass. Patients will be randomized to receive either botulinum toxin (50
units per fat pad, n=65) or normal saline/placebo (1 mL per fat pad, n=65) injected into
epicardial fat pads. All patients will receive standardized anesthetic, surgical, and
post-surgical care. The primary outcome in this study will be time to occurrence of
in-hospital POAF. Based on previous work and a pilot trial showing a pronounced reduction
(relative risk reduction 77%) in POAF after injecting botulinum into the epicardial fat pads,
the investigators anticipate a significant reduction in the risk for POAF with epicardial
botulinum in this cohort, which includes valve surgery patients.
Purpose of the study: A pilot study to determine whether injecting botulinum toxin into
epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation
(POAF) after cardiac surgery
Hypothesis to be tested: Botulinum toxin injected into the epicardial fat pads reduces POAF.
Design and Procedures: This will be a prospective randomized pilot trial of 130 patients
undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery via
median sternotomy with cardiopulmonary bypass. Patients <50 years of age, with chronic atrial
fibrillation, prior cardiac surgery, EF<25%, preoperative inotropic support, hepatic or renal
failure, known sensitivity to botulinum toxin, debilitating neuromuscular disease, or those
with a history of atrioventricular block will be excluded from the study. Prior to surgery,
all patients will have baseline Mini-Mental State Examination (MMSE) and blood sampling from
an indwelling arterial line or venipuncture for measurement of inflammatory and genomic
markers. Half of the patients will be randomized to receive injection of epicardial botulinum
toxin in addition to standard of care, as described below. The other half will receive
epicardial injection of normal saline.
Institution of cardiopulmonary bypass will be performed according to the routine surgical
protocol. After instituting CPB, botulinum toxin (or normal saline) injections will be
performed by the surgeon. This dose was selected given the prior report of its effectiveness
in preventing POAF after cardiac surgery in a small pilot study.(Pokushalov et al., 2014)
After completion of surgery and separation from CPB, patients will proceed along the
institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG
(telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and
will be defined as new-onset if it occurs postoperatively at any time before hospital
discharge. POAF, if it occurs, will be treated as per routine of care. POAF will be defined
as any detectable atrial fibrillation before discharge that lasts >30 seconds. On
postoperative day (POD) 4, a member of the study team will visit each patient to administer
the MMSE and capture a 5-minute ECG with a Holter monitor. In addition, patients will be
contacted monthly for 4 months and at one year after surgery for follow up, and medical
records will be reviewed for evidence of readmissions, arrhythmias, or other adverse events.
epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation
(POAF) after cardiac surgery
Hypothesis to be tested: Botulinum toxin injected into the epicardial fat pads reduces POAF.
Design and Procedures: This will be a prospective randomized pilot trial of 130 patients
undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery via
median sternotomy with cardiopulmonary bypass. Patients <50 years of age, with chronic atrial
fibrillation, prior cardiac surgery, EF<25%, preoperative inotropic support, hepatic or renal
failure, known sensitivity to botulinum toxin, debilitating neuromuscular disease, or those
with a history of atrioventricular block will be excluded from the study. Prior to surgery,
all patients will have baseline Mini-Mental State Examination (MMSE) and blood sampling from
an indwelling arterial line or venipuncture for measurement of inflammatory and genomic
markers. Half of the patients will be randomized to receive injection of epicardial botulinum
toxin in addition to standard of care, as described below. The other half will receive
epicardial injection of normal saline.
Institution of cardiopulmonary bypass will be performed according to the routine surgical
protocol. After instituting CPB, botulinum toxin (or normal saline) injections will be
performed by the surgeon. This dose was selected given the prior report of its effectiveness
in preventing POAF after cardiac surgery in a small pilot study.(Pokushalov et al., 2014)
After completion of surgery and separation from CPB, patients will proceed along the
institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG
(telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and
will be defined as new-onset if it occurs postoperatively at any time before hospital
discharge. POAF, if it occurs, will be treated as per routine of care. POAF will be defined
as any detectable atrial fibrillation before discharge that lasts >30 seconds. On
postoperative day (POD) 4, a member of the study team will visit each patient to administer
the MMSE and capture a 5-minute ECG with a Holter monitor. In addition, patients will be
contacted monthly for 4 months and at one year after surgery for follow up, and medical
records will be reviewed for evidence of readmissions, arrhythmias, or other adverse events.
Inclusion Criteria:
- Undergoing cardiac surgery with cardiopulmonary bypass via median sternotomy
- coronary artery bypass graft (CABG)
- valve surgery
- CABG + valve surgery
Exclusion Criteria:
- < 50years of age
- > 90years of age
- chronic AF or AF at the time of screening
- preoperative heart block (second degree or greater)
- LVEF < 25%
- renal failure
- hepatic failure
- known sensitivity to Botulinum toxin
- debilitating neuromuscular disease
- preoperative need for inotropes/vasopressors or intra-aortic balloon pump
- planned MAZE procedure
- history of catheter ablation for AF
- use of Vaughan-Williams class I or III drugs within 5 elimination half lives (or
within 2 months for amiodarone)
- undergoing minimally-invasive cardiac surgery
- prior cardiac surgery
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
